Scope and claims analysis for US Patent 12,005,118 (meloxicam + rizatriptan oral migraine treatment in patients with depression)
US Patent 12,005,118 claims a tightly defined oral combination method for treating migraine (including pain/aura and associated symptoms) in humans with a history of depression. The core claim 1 recites the combination dose ranges and the depression-history qualifier; dependent claims then narrow the rizatriptan dose, symptom timing (1–2–24 hours), migraine severity, photophobia/phonophobia/nausea, aura association, adherence to a specific meloxicam dose anchor (about 20 mg free acid or salt equivalent), pharmacokinetic timing via meloxicam Tmax thresholds (≤2 h and ≤1 h), and downstream “reduced use” of other pain medications by at least about 20%. Additional dependent claims lock in specific salts (rizatriptan benzoate) and meloxicam free acid/salt forms.
Because only claim text was provided and no bibliographic, prosecution-history, spec, or citation data is included, the analysis below is confined to claim scope construction and an actionable US landscape map at the level of plausible blocking/overlap categories created by these claim elements.
What does US Patent 12,005,118 claim protect for oral migraine therapy with meloxicam and rizatriptan?
Answer (practical scope): It protects a method of treating migraine by orally administering a meloxicam + rizatriptan combination with specific dose ranges and a patient qualifier (history of depression), plus a set of narrower performance and characterization limits (symptom reduction timing, severity, aura, photophobia/phonophobia/nausea, “reduced use” of other pain meds, and meloxicam Tmax thresholds).
Claim 1 is the gatekeeper: combination + depression history + migraine pain/aura
Claim 1 requires all of the following:
- Route: oral administration
- Actives: meloxicam + rizatriptan
- Dose ranges:
- meloxicam: about 15 mg to 30 mg
- rizatriptan: not explicitly dose-quantified in claim 1 (dose-locked in dependent claims)
- Indication + phenotype: treating a human with migraine pain or aura
- Patient qualifier: the human has a history of depression
This combination + depression-history qualifier is a major constraint. A competitor using the same drug pairing but without meeting the “history of depression” qualifier would fall outside claim 1 unless separate claims are broader.
Dependent claims add narrow layers that define enforceable “proof points”
Dependent claim themes:
- Dose form/dose precision (rizatriptan 8–13 mg range; meloxicam about 20 mg; rizatriptan benzoate; meloxicam free acid/salt)
- Clinical timing endpoints (pain reduction at 1 hour and 24 hours; photophobia/phonophobia reduction at 2 hours; nausea reduction at 2 hours)
- Migraine severity (“moderate to severe”)
- Migraine-associated symptoms (photophobia, phonophobia, nausea)
- Aura association
- Concomitant medication behavior (“reduced use” of other pain medication vs would have occurred without meloxicam; at least 20% reduction)
- PK timing (meloxicam Tmax ≤ 2 hours or ≤ 1 hour)
How broad are the dose ranges and what combination strengths does the patent cover?
Answer (dose coverage): The patent spans a meloxicam oral dose range in claim 1 and then narrows to specific strength benchmarks in dependent claims, with rizatriptan dose range and salt form locked in further dependents.
Meloxicam dose scope
- Claim 1: about 15 mg to 30 mg meloxicam
- Claim 6 and downstream: about 20 mg meloxicam free acid, or molar equivalent salt
Rizatriptan dose scope
- Claim 2: about 8 mg to 13 mg rizatriptan free base, or molar equivalent salt
- Claim 28: explicitly about 10 mg rizatriptan free base (or molar equivalent salt), paired with about 20 mg meloxicam
Salt/chemical form narrowing
- Claim 26: rizatriptan is rizatriptan benzoate
- Claim 27: meloxicam is free acid or a salt form
Scope implication for product design: A generic or branded combination product that uses meloxicam and rizatriptan but does not match (i) the depression-history qualifier and (ii) at least one dependent claim’s additional constraints will face a claim-coverage fight. The strongest overlap risk typically comes from matching both dose and timing endpoints (symptoms at 1–2–24 hours) and/or PK-defined meloxicam Tmax thresholds.
Does US 12,005,118 require “history of depression,” and how does that change infringement risk?
Answer: Yes. Claim 1 explicitly requires the treated human to have a history of depression. This is a patient-history qualifier, not just a formulation attribute.
What this means for method claim proof
To assert or defend infringement, the patentee typically needs evidence tied to:
- patient history of depression (documented diagnosis history, treatment records, or equivalent clinical definition used in the patent’s study protocol)
- migraine pain or aura outcome within defined time windows (for dependents)
Design-around logic (in-scope based on claim text only)
- A treatment population without depression history is less likely to satisfy claim 1.
- A product labeled broadly for migraine could still be found to induce infringement if prescribed to depression-history patients and if the prescribed regimen meets the other claim limitations.
What symptom and timing endpoints are claimed (1 hour, 2 hours, 24 hours)?
Answer: The patent ties infringement-ready endpoints to time-to-response windows for specific migraine-related symptoms.
Pain reduction timing
- Claim 3: reduction in migraine pain at 1 hour after administration
- Claim 4: reduction in migraine pain at 24 hours after administration
Photophobia / phonophobia timing
- Claim 8: photophobia reduction at 2 hours
- Claim 11: phonophobia reduction at 2 hours
Nausea timing
- Claim 14: nausea reduction at 2 hours
How the claim structure drives litigation strategy
These are “performance” dependent claims. In practice, they often become:
- the focus of clinical evidence in infringement cases
- the focus of experimental design in validity/obviousness disputes (depending on what prior art measured and when)
What migraine phenotypes are included: aura, moderate-to-severe, and associated symptoms?
Answer: The patent includes aura association and defines severity and symptom profiles in dependent claims.
Aura association
- Claim 1: migraine pain or aura (core)
- Claim 16: migraine associated with aura (dependent narrowing)
Severity
- Claim 5: human is suffering from moderate to severe migraine pain
Associated symptoms
- Claim 7: photophobia
- Claim 10: phonophobia
- Claim 13: nausea
Scope implication: A competitor that produces an oral combination could still reduce risk by ensuring clinical evidence and labeling/usage patterns do not map onto the same symptom-time combinations, but that is fact- and evidence-dependent.
How do the “reduced use of pain medication other than meloxicam” claims work?
Answer: The patent adds an outcomes-based dependent claim tied to reduced use of other pain medications, expressed both qualitatively and with a quantified threshold.
The behavioral/concomitant medication limitation
- Claim 17: reduced use of pain medication other than meloxicam (vs what would have occurred without receiving meloxicam)
- Claim 18: reduced by at least about 20%
Why this can matter in infringement and obviousness
- In infringement, it can require careful attribution of “would have occurred without meloxicam” counterfactual.
- In validity, prior art must be able to show similar reductions or explain why the result is not taught.
What PK constraint is claimed: meloxicam Tmax thresholds (≤2 hours and ≤1 hour)?
Answer: The patent claims meloxicam exposure timing using Tmax thresholds in dependent claims.
Tmax requirements
- Claim 19: meloxicam Tmax ≤ 2 hours
- Claim 20: meloxicam Tmax ≤ 1 hour
- Claim 24: meloxicam Tmax ≤ 2 hours (in the aura-dependent chain)
- Claim 25: meloxicam Tmax ≤ 1 hour (in the aura-dependent chain)
Practical enforcement consequences
- This turns the method claim into a regimen that depends on formulation and/or administration conditions that drive Tmax.
- Even when active drugs and doses match, if a competing oral product yields a different meloxicam Tmax profile, some dependent claims may not be met.
Which specific salts and forms are explicitly covered (rizatriptan benzoate; meloxicam free acid/salt)?
Answer: Dependent claims lock down specific chemical forms.
- Rizatriptan benzoate: Claim 26
- Meloxicam free acid or salt form: Claim 27
- Combination strength with specific meloxicam (about 20 mg) and rizatriptan (about 10 mg): Claim 28
Scope implication: A generic could potentially use different salt forms. If a competitor uses a rizatriptan salt other than benzoate, it may avoid Claim 26 while still potentially falling under broader claims that do not require benzoate (e.g., claim 2’s range uses “salt of rizatriptan” generally, not specifying benzoate).
What does the patent landscape likely look like around US 12,005,118 (blocking vs overlapping IP categories)?
Answer (landscape map based on claim elements): The enforceable “collision points” fall into five categories: (1) combination-method claims for migraine using meloxicam + rizatriptan; (2) specific dosing ranges and symptom-time endpoints; (3) patient-phenotype qualifiers (history of depression); (4) PK-linked Tmax-dependent claims; and (5) salt/formulation and oral delivery enabling Tmax timing.
Because no patent citations, assignee, filing dates, or family members were provided, the landscape below is expressed as the type of US patents and claim themes that typically surround a US combination-method patent with these features.
1) Combination-method patents for migraine: meloxicam + triptan
- Expected overlaps from earlier and co-existing US filings claiming oral combination therapies for migraine using:
- an NSAID (meloxicam or other NSAIDs) with
- a triptan (rizatriptan or other triptans)
- Your strongest relevance: any prior US patents that already claim the oral co-administration of these agents for migraine pain/aura.
2) Dose-range and salt-form combinations
- Likely adjacent claims define:
- meloxicam dose range (15–30 mg)
- rizatriptan dose range (8–13 mg)
- specific strength pairings (20 mg meloxicam + 10 mg rizatriptan)
- rizatriptan salt identity (benzoate)
3) Patient-history qualifiers: “history of depression” and migraine outcomes
- This is a distinctive element. Prior art might not use depression-history qualifiers. If earlier art does not, novelty arguments likely center on:
- stratification by depression history
- observed efficacy endpoints in that subgroup
4) Symptom endpoints at 1–2–24 hours
- Prior art that measures migraine response often uses defined endpoints (pain-free, pain reduction) at time points like 2 hours. Claiming at 1 hour and 24 hours can create incremental differences in novelty and non-obviousness.
5) PK-driven Tmax-dependent dependent claims
- Tmax constraints usually correlate to:
- formulation dissolution profiles (immediate vs modified release)
- excipient selection
- salt form and manufacturing changes
- A competitor’s oral product manufacturing method can become relevant even if actives and dosing match.
How many claim “independent coverage vectors” exist for enforceability?
Answer: One independent claim (claim 1) plus multiple dependent claims create multiple potential infringement paths. Even if one dependent constraint fails, others may still be met.
Coverage vectors by limitation type
- Core regimen: oral meloxicam (15–30 mg) + rizatriptan for migraine pain/aura in depression-history patients
- Dose-strength vector: rizatriptan 8–13 mg and/or about 20 mg meloxicam
- Endpoint timing vector: pain at 1 hour and/or 24 hours; photophobia/phonophobia/nausea at 2 hours
- Phenotype vector: moderate-to-severe; aura association
- Concomitant-medication behavior vector: ≥20% reduced use of other pain medications
- PK vector: meloxicam Tmax ≤2h and/or ≤1h
- Salt identity vectors: rizatriptan benzoate; meloxicam free acid/salt
What generic or combination-drug entry risks exist under this claim structure?
Answer: Risk concentrates where a generic/authorized combination is used in depression-history patients and where clinical and PK evidence aligns with at least one dependent claim path.
High-risk generic scenarios
- Oral co-administration (or approved fixed-dose combination) delivering:
- meloxicam roughly 20 mg (or within 15–30 mg range) and
- rizatriptan roughly 10 mg (or within 8–13 mg range)
- Regimens that demonstrate:
- meloxicam Tmax ≤2 hours or ≤1 hour
- symptom improvements at the claimed post-dose time points
- Real-world prescribing to patients with a history of depression
Lower-risk scenarios
- Different patient populations (no depression history)
- Products with meloxicam Tmax >2 hours (or >1 hour) such that dependent PK claims are not met
- Different rizatriptan salt identity that avoids benzoate-specific dependent claim (though not necessarily independent coverage)
What litigation and licensing leverage does this claim set create?
Answer: The combination’s enforcement leverage sits in the intersection of:
- a unique patient-history qualifier (depression history) and
- multiple measurable dependent constraints (time-to-response, concomitant-med reductions, Tmax).
Where settlement pressure typically concentrates
- If the defendant’s clinical dataset (or post-marketing real-world evidence) shows overlap with pain/symptom timing and Tmax thresholds, the dependent claims become strong bargaining chips.
- If those endpoints differ, defendants can aim to design around the dependent claims while still facing exposure on claim 1.
Key takeaways
- US 12,005,118 is a method-of-treatment patent for oral meloxicam + rizatriptan in humans with migraine pain or aura and a history of depression.
- Claim 1 sets the core scope: depression-history + oral combination + meloxicam 15–30 mg.
- Dependent claims narrow enforceability through dose precision, salt identity, clinical timing endpoints (1h, 2h, 24h), severity (moderate-to-severe), symptom set (photophobia/phonophobia/nausea), aura association, ≥20% reduced use of other pain meds, and meloxicam Tmax ≤2h or ≤1h.
- The practical entry risk for generics or combination products is highest when both clinical response timing and meloxicam PK (Tmax) match the dependent claim structures and when use occurs in depression-history patients.
FAQs
-
Can a product avoid infringement by changing only the rizatriptan salt form?
Dependent claim 26 requires rizatriptan benzoate; other dependent claims accept “salt of rizatriptan” generally, so changing salt may avoid only benzoate-specific coverage.
-
If a generic matches drug doses but misses the meloxicam Tmax threshold, what happens?
It may avoid the Tmax-dependent dependent claims (19/20/24/25), but claim 1 or other dependent claims could still be asserted if their remaining limitations are satisfied.
-
How do the “reduced use of pain medication other than meloxicam” claims get measured?
They are framed against a counterfactual (“without receiving meloxicam”) and then quantified at ≥20% reduction, making the evidentiary method central to infringement analysis.
-
Does the patent cover migraine without aura?
Claim 1 covers migraine pain or aura; dependent claim 16 narrows to aura-associated migraine.
-
What is the strongest enforceability angle in this patent for defendants?
The depression-history qualifier in claim 1 is a major factual gate, while the dependent claims provide multiple measurable targets for efficacy and PK timing.
References
No external sources were provided or cited in the input.
